studi
found
patient
sever
acut
respiratori
syndrom
sar
exhibit
rapid
dramat
decreas
number
circul
myeloid
plasmacytoid
dendrit
cell
mdc
pdc
first
week
ill
reduct
mdc
pdc
compar
healthi
individu
respect
slow
return
normal
cell
number
convalesc
week
ill
averag
addit
number
circul
cell
exhibit
milder
reduct
week
earlier
return
normal
mean
week
respect
signific
invers
correl
found
number
dc
tcell
subset
highdos
steroid
treatment
novel
find
thu
suggest
acut
sarscoronaviru
infect
probabl
contribut
initi
reduct
dc
tcell
subset
blood
highdos
steroid
administr
may
subsequ
exacerb
prolong
low
express
cell
subset
find
aid
frame
studi
immunopathogenesi
sar
worldwid
outbreak
sever
acut
respiratori
syndrom
sar
led
case
death
countri
first
half
year
beij
region
affect
epidem
report
case
death
shortli
descript
new
viral
diseas
novel
infecti
coronaviru
sarscov
identifi
pathogen
agent
clinic
observ
reveal
hematolog
chang
peripher
blood
acut
lung
injuri
major
clinic
characterist
sar
mark
lymphocytopenia
occur
patient
acut
phase
sar
tcell
subset
particularli
affect
degre
reduct
circul
lymphocyt
count
found
associ
diseas
sever
indic
host
immun
function
chang
involv
initi
progress
sar
although
acut
lung
injuri
hematolog
manifest
observ
patient
sar
mechan
underli
pathogenesi
sarscov
infect
yet
understood
dendrit
cell
dc
demonstr
function
orchestr
immun
respons
invad
pathogen
includ
bacteria
parasit
virus
although
dc
includ
multipl
subset
human
peripher
blood
dc
princip
group
least
two
distinct
subset
myeloid
dendrit
cell
mdc
plasmacytoid
dendrit
cell
pdc
base
lineag
phenotyp
function
differ
gener
human
mdc
wellequip
induc
polar
via
product
interleukin
il
tumor
necrosi
factor
tnf
properli
stimul
pdc
character
distinct
capac
produc
larg
amount
type
ifn
respons
viru
howev
function
dc
subset
flexibl
vivo
vari
accord
state
activ
natur
matur
stimuli
given
dc
recent
clinic
studi
laboratori
demonstr
numer
decreas
function
impair
mdc
pdc
subset
blood
patient
chronic
viral
infect
resembl
caus
human
immunodefici
viru
hiv
hepat
c
viru
hcv
hepat
b
viru
hbv
moreov
pdc
count
decreas
parallel
progress
hivrel
disord
current
whether
dc
particip
sar
still
unclear
sinc
pauciti
clinic
data
concern
dc
patient
condit
earli
evid
suggest
acut
lung
injuri
sar
patient
characterist
patholog
alter
may
induc
inflammatori
immun
cell
well
cytokin
chemokin
releas
steroid
treatment
believ
play
immunosuppress
role
confer
clinic
benefit
treatment
sar
though
random
clinic
trial
support
clinic
efficaci
avail
investig
role
dc
immun
pathogenesi
sarscov
infect
effect
steroid
dc
sar
patient
serial
examin
circul
mdc
pdc
subset
well
cell
sar
patient
receiv
steroid
treatment
addit
screen
express
sarscov
receptor
angiotensinconvert
enzym
peripher
dc
lymphocyt
popul
examin
associ
dc
number
specif
antibodi
gener
among
patient
thirtyon
male
fortythre
femal
five
patient
die
diseas
averag
age
patient
year
old
patient
high
fever
receiv
steroid
treatment
mild
sever
progress
consolid
chang
serial
chest
radiograph
one
side
lung
first
week
ill
pneumonia
sever
mark
mean
chest
radiograph
score
calcul
basi
averag
percentag
area
manifest
ground
glass
opacif
consolid
nodular
shadow
lung
maxim
score
equival
area
involv
overal
chest
radiograph
score
summat
score
lung
total
score
heparin
fresh
peripher
blood
sampl
obtain
patient
weekli
possibl
blood
sampl
total
avail
use
examin
dc
tcell
subset
studi
patient
began
receiv
analys
peripher
dc
tcell
subset
day
sinc
diseas
onset
twentyf
blood
sampl
healthi
donor
recruit
control
plasma
sampl
isol
peripher
blood
centrifug
store
detect
sarscov
rna
cytokin
specif
antibodi
studi
protocol
approv
ethic
committe
unit
written
inform
consent
obtain
subject
patient
receiv
ribavirin
steroid
combin
therapi
therapeut
dose
methylprednisolon
includ
mgday
mgday
mgday
intraven
day
base
clinic
manifest
radiograph
deterior
po
decreas
high
fever
ventil
patient
time
commenc
corticosteroid
ribavirin
therapi
vari
individu
patient
except
patient
steroid
treatment
start
first
week
onset
ill
total
dose
steroid
administr
day
divid
twice
daili
iv
addit
sar
individu
fever
dyspnea
chest
radiographi
greatli
improv
dose
steroid
gradual
reduc
final
withdrew
possibl
analysi
dc
subset
heparin
fresh
peripher
blood
ad
tube
incub
mix
lineag
cocktail
fluorescein
isothiocyan
fitc
conjug
monoclon
antibodi
mab
includ
mab
percpconjug
antihladr
mab
phycoerythrein
pe
conjug
mab
isotyp
bd
pharmingen
san
diego
ca
separ
ad
tube
tube
incub
min
afterward
ml
facsi
lyse
solut
bd
pharmingen
ad
sampl
incub
room
temperatur
min
dark
wash
twice
pb
cell
fix
paraformaldehyd
threecolor
flow
cytometr
analysi
perform
use
facscalibur
becton
dickinson
san
jose
ca
circul
mdc
defin
lineag
hladr
pdc
defin
lineag
hladr
fig
percentag
absolut
number
mdc
pdc
calcul
basi
total
peripher
lymphocyt
monocyt
absolut
count
determin
autom
differenti
blood
count
cell
analyz
simultesttm
imklymphocyt
kit
bd
bioscienc
san
jose
ca
brief
heparin
fresh
peripher
blood
cell
separ
incub
mab
fitcconjug
peconjug
fitcconjug
peconjug
incub
kept
min
follow
lysi
red
blood
cell
wash
fixat
stain
cell
mention
lymphocyt
popul
gate
perform
accord
manufactur
instruct
peripher
blood
mononuclear
cell
pbmc
incub
optim
biotinyl
goatantihuman
ectodomain
antibodi
r
minneapoli
mn
room
temperatur
h
wash
twice
pb
cell
divid
separ
tube
individu
incub
peor
fitcconjug
mab
bd
pharmingen
miltenyi
biotec
gladbach
germani
togeth
complementari
fitcor
peconjug
streptavidin
r
min
dark
afterward
cell
wash
fix
analysi
aforement
vero
hela
cell
use
posit
neg
control
stain
respect
method
employ
previou
studi
base
public
modif
brief
rna
extract
directli
plasma
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
viral
rna
amplifi
nest
reversetranscript
polymeras
chain
reaction
rtpcr
use
two
pair
primer
outer
sens
antisens
primer
inner
senseantisens
primer
product
analyz
electrophoresi
agaros
gel
contain
agml
ethidium
bromid
viral
sequenc
confirm
dna
sequenc
analysi
fig
identif
myeloid
plasmacytoid
dendrit
cell
mdc
pdc
flow
cytometr
analysi
fresh
peripher
blood
mononuclear
cell
pbmc
gate
total
peripher
leukocyt
base
forward
side
scatter
percphladr
fitclineag
cell
pbmc
identifi
mdc
subpopul
pdc
subpopul
respect
plasma
antisarscov
igg
antibodi
detect
accord
instruct
commerci
avail
enzymelink
immunosorb
assay
elisa
kit
huadajibiai
biotech
beij
indirect
assay
employ
kit
use
cultureobtain
sarscov
antigen
captur
antibodi
od
valu
judg
posit
data
analyz
use
spss
softwar
spss
inc
chicago
illinoi
statist
signific
differ
group
determin
appli
unpair
student
test
spearman
correl
analysi
perform
number
dc
tcell
subset
steroid
dosag
administr
day
sampl
p
valu
less
consid
signific
differ
combin
sever
marker
use
defin
mdc
lineag
pdc
lineag
blood
shown
fig
mean
number
peripher
mdc
pdc
sar
patient
significantli
reduc
week
patient
vs
healthi
control
vs
mdc
p
al
vs
pdc
p
rapidli
decreas
minimum
level
week
ill
mdc
pdc
respect
point
reduct
mdc
pdc
compar
healthi
control
number
mdc
pdc
gradual
increas
reach
normal
level
mean
week
mdc
week
pdc
onset
ill
respect
fig
addit
prolong
period
decreas
number
dc
observ
sar
patient
critic
statu
continu
week
ill
unit
patient
receiv
steroid
treatment
first
week
ill
also
exhibit
decreas
number
circul
mdc
vs
p
pdc
vs
p
respect
compar
healthi
control
higher
amount
mdc
pdc
patient
steroid
treatment
fig
although
sar
patient
similar
peripher
leukocyt
count
broader
rang
variat
l
compar
healthi
control
l
first
week
ill
lymphocytopenia
observ
time
case
lymphocyt
count
less
averag
level
healthi
control
mean
number
circul
cell
patient
respect
week
ill
reduct
respect
compar
healthi
control
cell
cell
afterward
number
cell
progress
increas
reach
normal
level
week
week
ill
respect
fig
patient
receiv
steroid
treatment
first
week
ill
cell
vs
p
cell
vs
al
p
also
significantli
lower
compar
healthi
control
addit
though
patient
steroid
therapi
exhibit
slight
lower
amount
tcell
subset
without
steroid
therapi
differ
two
group
fig
evalu
effect
steroid
treatment
circul
dc
tcell
subset
patient
categor
three
group
base
dose
steroid
treatment
regimen
mgday
mgday
mgday
peripher
mdc
pdc
tcell
number
monitor
weekli
individu
consid
delay
effect
steroid
dose
administ
day
sampl
use
analysi
shown
fig
steroid
administr
invers
correl
absolut
number
circul
dc
tcell
subset
gener
patient
group
receiv
higher
dose
steroid
lower
number
circul
mdc
pdc
cell
slower
restor
cell
number
normal
level
patient
group
receiv
lower
dose
steroid
signific
invers
correl
steroid
dosag
number
cell
dc
subset
observ
week
onset
ill
correl
sustain
throughout
cours
steroid
administr
subject
examin
contrast
though
signific
invers
correl
also
observ
steroid
dosag
number
cell
durat
decreas
number
cell
tcell
subset
shorter
addit
clear
correl
observ
chang
number
cell
dc
tcell
subset
ribavirin
treatment
studi
cell
stain
antibodi
specif
cd
marker
see
materi
method
employ
flow
cytometr
analysi
screen
result
show
except
posit
control
vero
cell
blood
cell
test
includ
dc
tcell
subset
neg
surfac
express
data
shown
studi
sar
patient
weekli
monitor
peripher
dc
subset
antisarsigg
antibodi
throughout
cours
diseas
investig
whether
dynam
chang
dc
subset
associ
antibodi
respons
patient
artifici
divid
group
dchigh
group
n
dclow
group
n
basi
restor
mdc
pdc
number
convalesc
phase
week
week
patient
assign
dchigh
group
number
mdc
pdc
least
reach
higher
mean
valu
healthi
control
period
otherwis
patient
assign
dclow
group
way
group
similar
dc
count
initi
week
ill
dchigh
group
earlier
increas
full
restor
dc
number
fig
b
shown
fig
dchigh
group
better
igg
antisarscov
antibodi
respons
dclow
group
suggest
persist
reduct
mdc
pdc
subset
might
affect
gener
specif
antibodi
sarscov
infect
previous
specul
determin
profil
dc
tcell
subset
number
clinic
statu
steroid
ribavirin
administr
well
viral
rna
specif
antibodi
statu
overal
select
repres
individu
case
sar
examin
paramet
throughout
cours
sar
shown
fig
administr
steroid
often
attenu
high
fever
decreas
high
bodi
temperatur
patient
normal
bodi
temperatur
day
receiv
highdos
steroid
treatment
mgday
sinc
day
diseas
time
show
first
line
upper
tabl
patient
also
receiv
steroid
therapi
mgday
begin
second
day
ill
normal
bodi
temperatur
day
lower
level
mdc
pdc
analyz
patient
similar
condit
like
patient
fig
also
display
sarscov
rna
specif
antibodi
detect
plasma
patient
coexist
viral
rna
antibodi
observ
patient
five
patient
clinic
critic
statu
one
case
patient
gener
noncrit
statu
patient
year
old
male
patient
year
old
male
exhibit
extrem
decreas
circul
number
dc
tcell
subset
throughout
highdos
steroid
treatment
succumb
sar
develop
sever
immun
suppress
impair
favor
multipl
organ
failur
develop
aspergillosi
previous
report
patient
surviv
also
low
peripher
cell
express
receiv
highdos
steroid
treatment
chang
revers
convalesc
phase
reduct
suspens
steroid
administr
sar
acut
selflimit
diseas
clinic
progress
mostli
uniform
triphas
pattern
includ
activ
viral
replic
phase
day
ill
immun
storm
lung
damag
phase
convalesc
phase
roughli
day
though
three
phase
probabl
overlap
studi
longitudin
observ
demonstr
first
time
rapid
dramat
declin
sustain
period
low
level
peripher
subset
mdc
pdc
simultan
observ
signific
revers
decreas
tcell
popul
consist
previou
report
sar
character
peak
viral
load
respiratori
secret
around
day
ill
subsequ
decreas
find
show
peak
reduct
dc
subset
often
occur
around
day
diseas
partli
overlap
lung
damag
phase
sinc
patient
sar
administ
steroid
week
ill
initi
reduct
dc
tcell
subset
may
due
mainli
acut
sarscov
infect
previou
report
suggest
sarscov
infect
probabl
induc
mild
immunosuppress
immun
function
suppress
highdos
steroid
treatment
howev
still
unclear
human
immun
system
impair
sar
infect
find
show
amount
dc
cell
invers
correl
intens
highdos
steroid
treatment
sar
patient
fig
though
data
interpret
caution
see
notabl
dc
subset
blood
exhibit
signific
delay
restor
normal
number
compar
clinic
recoveri
resolut
pulmonari
damag
studi
addit
find
suggest
lower
count
mdc
pdc
subset
may
associ
poor
prognosi
patient
previou
studi
low
lymphocyt
count
like
use
steroid
high
dose
mgday
week
exacerb
prolong
decreas
number
pdc
mdc
sar
patient
therefor
longterm
use
highdos
steroid
therapi
potenti
riski
especi
sar
patient
critic
statu
condit
like
diabet
heart
diseas
compar
mdc
tcell
subset
pdc
exhibit
greater
decreas
slower
restor
number
suggest
minimum
circul
pdc
like
sensit
steroid
administr
describ
shodel
et
al
addit
direct
effect
sarscov
infect
follow
mechan
may
account
reduct
circul
mdc
pdc
tcell
subset
sar
patient
steroid
treatment
may
induc
apoptosi
activ
cell
tlymphocyt
movement
intravascular
compart
particular
decreas
dc
subset
might
caus
preferenti
traffick
recruit
cell
patholog
pulmonari
tissu
site
natur
circul
blood
report
tuberculosi
glucocorticoid
may
suppress
differenti
matur
dc
subset
induc
apoptosi
tissu
sequestr
singli
togeth
virus
may
directli
infect
immunocyt
caus
impair
cell
popul
occur
hcv
infect
howev
still
unclear
sarscov
impair
human
immun
system
pathogenesi
sarscov
infect
sarscov
replic
observ
pbmc
mdc
abl
interact
protein
bind
viru
even
though
function
receptor
sarscov
find
demon
fig
analysi
associ
myeloid
dendrit
cell
subset
mdc
pdc
specif
antibodi
profil
patient
sar
divid
dchigh
group
n
dclow
group
n
base
dynam
chang
circul
dc
subset
convalesc
phase
ill
dchigh
group
exhibit
earlier
increas
full
restor
cell
number
dclow
group
b
plasma
igg
antibodi
sarscov
monitor
weekli
shown
averag
optic
densiti
od
group
determin
elisa
c
od
valu
consid
posit
data
express
mean
top
standard
deviat
fig
longitudin
observ
repres
sar
patient
cours
ill
patient
sar
upper
tabl
show
sever
pneumonia
detect
sar
coronaviru
rna
specif
igg
antibodi
plasma
bodi
temperatur
record
differ
day
lower
figur
show
dynam
alter
number
circul
mdc
pdc
tcell
subset
well
dose
repres
given
color
steroid
ribavirin
administ
axi
dc
calibr
patient
patient
respect
sever
pneumonia
mark
mean
chest
radiograph
score
maximum
score
patholog
lung
total
score
patholog
lung
accord
ho
et
al
find
patient
detail
result
strate
lack
express
human
dc
subset
lymphocyt
consist
previou
find
thu
unlik
decreas
number
circul
dc
tcell
subset
vivo
due
direct
injuri
sarscov
infect
cell
molecul
address
issu
investig
recent
report
sarscov
may
infect
macrophag
cellular
phagocytosi
enter
mdc
viral
bind
surfac
dcsign
receptor
unclear
mechan
sinc
dc
rare
express
dcsign
vivo
recent
studi
shown
viral
infect
usual
induc
product
larg
amount
ifna
pdc
host
defens
viru
howev
found
significantli
lower
level
plasma
ifna
pgml
patient
acut
phase
sar
ill
healthi
control
pgml
find
accord
observ
reduct
pdc
number
precis
relationship
remain
clarifi
studi
unabl
design
random
control
investig
emerg
associ
sar
outbreak
limit
avail
clinic
specimen
restrict
sampl
size
group
function
analysi
mdc
pdc
insuffici
thu
difficult
conclud
certainti
observ
reduct
dc
subset
number
entir
result
steroid
treatment
hand
clinic
observ
inde
suggest
dose
steroid
impact
number
dc
well
tcell
subset
sinc
sar
patient
noncrit
critic
statu
exhibit
reduct
cell
number
soon
receiv
steroid
therapi
fig
previou
studi
report
mdc
pdc
subset
may
affect
product
antibodi
studi
observ
interest
find
sar
patient
faster
restor
mdc
pdc
subset
peripher
blood
better
antibodi
respons
sarscov
patient
slower
restor
mdc
pdc
subset
howev
find
interpret
caution
sinc
use
highdos
steroid
common
critic
case
whether
find
directli
associ
impair
mdc
pdc
remain
clarifi
conclus
observ
first
time
dramat
revers
decreas
circul
subset
mdc
pdc
sar
patient
addit
find
suggest
acut
sarscov
infect
may
contribut
rapid
initi
reduct
circul
mdc
pdc
subsequ
steroid
administr
particularli
high
dose
week
probabl
exacerb
prolong
decreas
number
dc
subset
well
tcell
subset
find
use
frame
studi
immunopathogenesi
sar
thogenesi
studi
beij
natur
scienc
foundat
